Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer.

Cheema, P K; Rothenstein, J; Melosky, B; Brade, A; Hirsh, V

Cheema, P K; Rothenstein, J; Melosky, B; Brade, A; Hirsh, V.

Affiliation

Cheema PK; William Osler Health System, Brampton/Toronto, and University of Toronto, Toronto, ON.
Rothenstein J; R.S. McLaughlin Durham Regional Cancer Centre, Oshawa, and Queen's University, Kingston, ON.
Melosky B; BC Cancer-Vancouver and University of British Columbia, Vancouver, BC.
Brade A; Peel Regional Cancer Centre, Mississauga, and University of Toronto, Toronto, ON.
Hirsh V; Royal Victoria Hospital and McGill University, Montreal, QC.

Curr Oncol ; 26(1): 37-42, 2019 02.

Article in En | MEDLINE | ID: mdl-30853796

Subject(s)

Antibodies, Monoclonal/therapeutic use; Antineoplastic Agents, Immunological/therapeutic use; Carcinoma, Non-Small-Cell Lung/therapy; Chemoradiotherapy; Lung Neoplasms/therapy; Carcinoma, Non-Small-Cell Lung/pathology; Humans; Lung Neoplasms/pathology; Neoplasm Staging

Key words

Lung cancer; immunotherapy; stage III disease

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Chemoradiotherapy / Antineoplastic Agents, Immunological / Lung Neoplasms / Antibodies, Monoclonal Limits: Humans Language: En Journal: Curr Oncol Year: 2019 Type: Article

Fulltext

XML

PubMed Links

Search on Google